dCELL? technology presented at Royal Society event

RNS Number : 2482R

Tissue Regenix Group PLC

10 September 2014

 



Tissue Regenix Group Plc

Tissue Regenix's dCELL® heart valve technology to be presented at prestigious Royal Society event

YORK, 10^th September 2014 - Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix" or "the Group"), the regenerative medical devices company, announces that its long-term clinical collaborator, Professor Francisco da Costa, has been asked to present the findings from his study into the Group's dCELL® heart valve at the 6th Biennial Heart Valve and Tissue Engineering Meeting at the Royal Society in London, on 12^th September 2014.

The study findings suggest that fresh decellularised human heart valves, developed using Tissue Regenix's patented dCELL® technology, could provide a more effective treatment than cryopreserved decellularised pulmonary valve substitutes.

Professor Francisco da Costa is an internationally renowned cardiac surgeon from Pontifical University of Parana, Brazil, and the data in the report has been accumulated from more than 160 patient implants undertaken during Ross Procedures at his institution between 2005 and 2013 with follow-up review and patient monitoring up to the present date. 

Key findings of the study include that the fresh dCELL® heart valve has shown:

·     No reoperation up to now in a relatively young patient population (mean age 30 years)

·     No peak gradient above 40mmHg for up to six years

·     Significantly higher freedom from valve dysfunction (97% vs 85%)

·     No calcification

·     Partial re-population of the grafts

·     Particularly good results in younger patients

·     First indication that commonly used standard cryopreservation is unnecessary

Tissue Regenix's dCELL® technology decellularises human donor heart valves, producing an inert scaffold which is implanted into the patient to act as a mechanical scaffold that is populated by the patient's own cells. The dCELL® heart valve regenerates to become part of the patient's body, providing a more durable repair with proven significantly reduced risk of rejection and infection.

Antony Odell, CEO of Tissue Regenix commented: "We are excited to see continued recognition for the effectiveness of the dCELL® heart valve technology, especially at this prestigious Royal Society Biennial Heart Valve and Tissue Engineering Meeting in London.

"Professor da Costa has collaborated with Tissue Regenix for more than eight years to develop new, regenerative medicine treatments for patients with heart disease, and the data based on his studies show strong results and great promise for the dCELL® heart valve technology, targeted at the global tissue heart valve market which is worth in excess of $1.0bn a year.

"This latest announcement comes on the back of further, recent positive updates on the development and commercialisation of our dCELL® treatments. This includes the DermaPure™ decellularised dermal allograft, where the US commercialisation continues at pace with initial orders having been received, and shipped to customers and continued progress being made in securing approvals by hospital new product evaluation committees - a key element in the inpatient sales process.

- ENDS -

For Further Information

Tissue Regenix Group Plc:                                                           [phone]

Antony Odell

Ian Jefferson

Jefferies International Ltd:                                                         [phone]

Simon Hardy

Harry Nicholas

Newgate Communications:                                                        [phone]

Andrew Adie                                                                    

Stephanie Dobbs                                                            

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

 

Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States- 'Tissue Regenix Wound Care Inc.', as part of its commercialisation strategy for its dCELL® technology platform.

 

END

 

 

NRALLMRTMBBMBPI